MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples.
Trichosporon
Iran
amplified fragment length polymorphism
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry
susceptibility
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
27
02
2021
accepted:
06
05
2021
pubmed:
18
5
2021
medline:
16
11
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
Trichosporonosis is an emerging fungal infection caused by Trichosporon species, a genus of yeast-like fungi, which are frequently encountered in human infections ranging from mild cutaneous lesions to fungemia in immunocompromised patients. The incidence of trichosporonosis has increased in recent years, owing to higher numbers of individuals at risk for this infection. Although amphotericin B, posaconazole and isavuconazole are generally effective against Trichosporon species, some isolates may have variable susceptibility to these antifungals. Herein, we evaluated the species distribution, genetic diversity and antifungal susceptibility profiles of Trichosporon isolates in Iran. The yeasts were identified by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). Phylogenetic analysis was performed based on amplified fragment length polymorphism (AFLP). The in vitro susceptibilities of eight antifungal agents were analysed using the Clinical and Laboratory Standards Institute broth microdilution methods. The isolates belonged to the species T asahii (n = 20), T japonicum (n = 4) and T faecale (n = 3). A dendrogram of the AFLP analysis demonstrated that T asahii and non-asahii Trichosporon strains (T japonicum and T faecale) are phylogenetically distinct. While voriconazole was the most active agent (GM MIC = 0.075 μg/ml), high fluconazole MICs (8 μg/ml) were observed for a quarter of Trichosporon isolates. The GM MIC value of amphotericin B for T asahii and non-asahii Trichosporon species was 0.9 μg/ml. The distribution and antifungal susceptibility patterns of the identified Trichosporon species could inform therapeutic choices for treating these emerging life-threatening fungi.
Sections du résumé
BACKGROUND
BACKGROUND
Trichosporonosis is an emerging fungal infection caused by Trichosporon species, a genus of yeast-like fungi, which are frequently encountered in human infections ranging from mild cutaneous lesions to fungemia in immunocompromised patients. The incidence of trichosporonosis has increased in recent years, owing to higher numbers of individuals at risk for this infection. Although amphotericin B, posaconazole and isavuconazole are generally effective against Trichosporon species, some isolates may have variable susceptibility to these antifungals.
OBJECTIVES
OBJECTIVE
Herein, we evaluated the species distribution, genetic diversity and antifungal susceptibility profiles of Trichosporon isolates in Iran.
METHODS
METHODS
The yeasts were identified by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). Phylogenetic analysis was performed based on amplified fragment length polymorphism (AFLP). The in vitro susceptibilities of eight antifungal agents were analysed using the Clinical and Laboratory Standards Institute broth microdilution methods.
RESULTS
RESULTS
The isolates belonged to the species T asahii (n = 20), T japonicum (n = 4) and T faecale (n = 3). A dendrogram of the AFLP analysis demonstrated that T asahii and non-asahii Trichosporon strains (T japonicum and T faecale) are phylogenetically distinct. While voriconazole was the most active agent (GM MIC = 0.075 μg/ml), high fluconazole MICs (8 μg/ml) were observed for a quarter of Trichosporon isolates. The GM MIC value of amphotericin B for T asahii and non-asahii Trichosporon species was 0.9 μg/ml.
CONCLUSIONS
CONCLUSIONS
The distribution and antifungal susceptibility patterns of the identified Trichosporon species could inform therapeutic choices for treating these emerging life-threatening fungi.
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
918-925Subventions
Organisme : National Institutes for Medical Research Development
ID : 971039
Organisme : Mazandaran University of Medical Sciences
ID : 3160
Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Colombo AL, Padovan AC, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev. 2011;24(4):682-700.
Francisco EC, de Almeida Junior JN, de Queiroz TF, et al. Species distribution and antifungal susceptibility of 358 Trichosporon clinical isolates collected in 24 medical centres. Clinical Microbiol Infect. 2019;25(7):909.e901.
Guo LN, Yu SY, Hsueh PR, et al. Invasive infections due to Trichosporon: species distribution, genotyping, and antifungal susceptibilities from a multicenter study in China. J Clin Microbiol. 2019;57(2):e01505-18. https://doi.org/10.1128/JCM.01505-18
Liu XZ, Wang QM, Göker M, et al. Towards an integrated phylogenetic classification of the Tremellomycetes. Stud Mycol. 2015;81:85-147.
Mariné M, Brown NA, Riaño-Pachón DM, Goldman GH. On and under the skin: emerging Basidiomycetous yeast infections caused by Trichosporon species. PLoS Pathog. 2015;11(7):e1004982. https://doi.org/10.1371/journal.ppat.1004982
Taverna CG, Córdoba S, Murisengo OA, Vivot W, Davel G, Bosco-Borgeat ME. Molecular identification, genotyping, and antifungal susceptibility testing of clinically relevant Trichosporon species from Argentina. Med Mycol. 2014;52(4):356-366.
de Almeida Júnior JN, Figueiredo DS, Toubas D, et al. Usefulness of matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry for identifying clinical Trichosporon isolates. Clinical Microbiol Infect. 2014;20(8):784-790.
Aslani N, Janbabaei G, Abastabar M, et al. Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infect Dis. 2018;18(1):24.
Francisco EC, de Almeida Junior JN, Queiroz-Telles F, et al. Correlation of Trichosporon asahii genotypes with anatomical sites and antifungal susceptibility profiles: data analyses from 284 isolates collected in the last 22 years across 24 medical centers. Antimicrob Agents Chemother. 2021;65(3):e01104-20.
Li HM, Du HT, Liu W, Wan Z, Li RY. Microbiological characteristics of medically important Trichosporon species. Mycopathologia. 2005;160(3):217-225.
Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition, M60 (1st edn). Wayne: CLSI. 2017.
Arabatzis M, Abel P, Kanellopoulou M, et al. Sequence-based identification, genotyping and EUCAST antifungal susceptibilities of Trichosporon clinical isolates from Greece. Clinical Microbiol Infect. 2014;20(8):777-783. https://doi.org/10.1111/1469-0691.12501
Kalkanci A, Sugita T, Arikan S, et al. Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients. Med Mycol. 2010;48(1):141-146.
Ağirbasli H, Bilgen H, Ozcan SK, et al. Two possible cases of Trichosporon infections in bone-marrow-transplanted children: the first case of T. japonicum isolated from clinical specimens. Jpn J Infect Dis. 2008;61(2):130-132.
Bongomin F, Otu A, Calisti G, et al. Trichosporon japonicum Fungemia and ventricular assist device infection in an immunocompetent patient. Open Forum Infect Dis. 2019;6(9):ofz343.
do Espírito Santo EPT, Monteiro RC, da Costa ARF, Marques-da-Silva SH. Molecular identification, genotyping, phenotyping, and antifungal susceptibilities of medically important Trichosporon, Apiotrichum, and Cutaneotrichosporon Species. Mycopathologia. 2020;185(2):307-317.
Rastogi V, Honnavar P, Rudramurthy SM, Pamidi U, Ghosh A, Chakrabarti A. Molecular characterisation and antifungal susceptibility of clinical Trichosporon isolates in India. Mycoses. 2016;59(8):528-534.
Chagas-Neto TC, Chaves GM, Melo AS, Colombo AL. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J Clin Microbiol. 2009;47(4):1074-1081.
Cho O, Matsukura M, Sugita T. Molecular evidence that the opportunistic fungal pathogen Trichosporon asahii is part of the normal fungal microbiota of the human gut based on rRNA genotyping. Int J Infect Dis. 2015;39:87-88.
Padovan ACB, Rocha W, Toti ACM, Freitas de Jesus DF, Chaves GM, Colombo AL. Exploring the resistance mechanisms in Trichosporon asahii: Triazoles as the last defense for invasive trichosporonosis. Fungal Genetics Biol. 2019;133:103267.
Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother. 2005;49(10):4026-4034.
Wolf DG, Falk R, Hacham M, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol. 2001;39(12):4420-4425.
Kuo SH, Lu PL, Chen YC, et al. The epidemiology, genotypes, antifungal susceptibility of Trichosporon species, and the impact of voriconazole on Trichosporon fungemia patients. J Formos Med Assoc. 2020;S0929-6646(20)30607-0. https://doi.org/10.1016/j.jfma.2020.12.007
Taj-Aldeen SJ, Al-Ansari N, El Shafei S, et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol. 2009;47(6):1791-1799.
de Almeida Júnior JN, Hennequin C. Invasive Trichosporon Infection: a systematic review on a re-emerging fungal pathogen. Front Microbiol. 2016;7:1629.